Industry News

The Zydus Group with an overarching purpose of empowering people with freedom to live healthier and more fulfilled lives, is an innovative, global pharmaceutical company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group employs over 23000 people worldwide and is driven by its mission to unlock new possibilities in life-sciences through quality healthcare solutions that impact lives. The group aspires to become a global life-sciences company transforming lives through pathbreaking discoveries.

The 7th Udai Pareek Memorial Oration was delivered virtually by Mr. Sanjiv Mehta, Chairman & MD, Hindustan Unilever Ltd. (HUL), on a current subject; of Organization and Leadership in a BANI World. The lecture was presided over by Padmavibhushan Dr. Raghunath Anant Mashelkar, National Research Professor and Chairman of the National Innovation Foundation.

Roche announced that Actemra/RoActemra (tocilizumab) intravenous (IV) has been granted World Health Organization (WHO) prequalification. Prequalification is a confirmation by WHO that Actemra/RoActemra meets the WHO standards for quality, safety and efficacy for the treatment of COVID-19 in adults who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation. It helps procurers in low- and middle-income countries identify priority medicines to improve access to care and support better health.

Quris, an artificial intelligence (AI) innovator disrupting the pharmaceutical arena, today announced it has signed an agreement with Merck KGaA, Darmstadt, Germany, a leading science and technology company, allowing Merck KGaA, Darmstadt, Germany to assess Quris’ BioAI safety prediction platform, comparing it to traditional in vitro and in vivo approaches.

The U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for Dupixent® (dupilumab) as an add-on maintenance treatment for children aged 6 months to 5 years with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. The target action date for the FDA decision on this investigational use is June 9, 2022.

IIHMR University, Jaipur on Wednesday inaugurated its 26th Pradanya Annual Global Conference on Innovations in Healthcare and Education: The Decade of Acceleration for Global Goals, a 3-day conference attended by 30 speakers from 25+ country and over 2000 delegates. Dr. P.R. Sodani, President, IIHMR University welcomed the guest, speakers, and delegates in the inaugural session and introduced the conference theme and tracks to the audience. Dr.

Global pharma major Lupin Limited announced that it has received approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application, Arformoterol Tartrate Inhalation Solution 15 mcg (base)/2 ml, Unit-dose Vials to market a generic equivalent of Brovana ® Inhalation Solution, 15 mcg /2 ml of Sunovion Pharmaceuticals Inc. (Sunovion).

Glenmark Pharmaceuticals Limited a global, innovation-driven pharmaceutical company and Canadian pharmaceutical company SaNOtize Research & Development Corp. today announced launch of its Nitric Oxide Nasal Spray under the brand name FabiSpray in India; for the treatment of adult patients with COVID-19 who have high risk of progression of the disease. Glenmark earlier received manufacturing and marketing approval from the Drugs Controller General of India (DCGI) for NONS as part of the accelerated approval process.

The U.S. Food and Drug Administration FDA has approved Enjaymo sutimlimab-jome to decrease the need for red blood cell transfusion due to hemolysis in adults with cold agglutinin disease CAD. Enjaymo is the first and only approved treatment for people with CAD and works by inhibiting the destruction of red blood cells hemolysis.